Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
human allogeneic umbilical cord mesenchymal stromal cells
- Development stage
- Unknown
- Lead developer
- Ottawa Hospital Research Institute
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
This investigational cell therapy consists of human allogeneic umbilical cord-derived mesenchymal stromal cells (UC-MSCs) developed by the Ottawa Hospital Research Institute. It is specifically designed for the prevention of bronchopulmonary dysplasia (BPD) in extremely low gestational age infants (less than 28 weeks gestation) who remain ventilator-dependent. Administered intravenously in three weekly doses, these cells exert pleiotropic effects, including immunomodulatory and regenerative properties, which have demonstrated lung-protective capabilities in preclinical models of neonatal lung injury. The therapy aims to reduce inflammation and promote lung repair, thereby preventing the development of chronic lung disease in this vulnerable population.
- Other names
- human umbilical cord-derived mesenchymal stromal cellsumbilical cord mesenchymal stromal cellshuman allogeneic umbilical cord mesenchymal stromal cells-Ottawa Hospital Research Institute-bronchopulmonary dysplasia
Beyond the preview
Go deeper on human allogeneic umbilical cord mesenchymal stromal cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on human allogeneic umbilical cord mesenchymal stromal cells.